12.3 Microsatellite Instability & DNA Mismatch Repair
Key Takeaways
- Microsatellites are short tandem repeat (STR) sequences (1–6 bp) scattered throughout the genome that are exceptionally vulnerable to DNA polymerase slippage during replication.
- The DNA mismatch repair (MMR) system operates via two functional heterodimers: MutSalpha (MSH2/MSH6) or MutSbeta (MSH2/MSH3) for mismatch recognition, and MutLalpha (MLH1/PMS2) for strand excision coordination; MSH2 and MLH1 are dominant obligate proteins whose loss degrades their secondary partners (MSH6 and PMS2, respectively).
- Deficient MMR (dMMR) leads to Microsatellite Instability-High (MSI-H), which arises either from hereditary germline mutations in Lynch syndrome (MLH1, MSH2, MSH6, PMS2, or EPCAM deletion) or from sporadic somatic hypermethylation of the MLH1 promoter (often accompanied by BRAF V600E).
- Clinical testing employs IHC for MMR protein expression, PCR-capillary electrophoresis using the 5-marker Bethesda panel (2 mono- + 3 dinucleotide markers) or the Promega Pentaplex panel (5 quasimonomorphic mononucleotide markers: BAT-25, BAT-26, NR-21, NR-24, MONO-27), or NGS-based computational algorithms.
- MSI-H / dMMR tumors accumulate hundreds of somatic frameshift mutations, creating high neoantigen loads and high tumor mutational burden (TMB-H >= 10 mut/Mb), conferring profound sensitivity to immune checkpoint inhibitors (anti-PD-1/PD-L1 antibodies like Pembrolizumab) across all solid tumor types.
12.3 Microsatellite Instability & DNA Mismatch Repair
Quick Summary: Microsatellite Instability (MSI) is the phenotypic hallmark of deficient DNA Mismatch Repair (dMMR), characterized by the genome-wide hyperaccumulation of insertion and deletion mutations within short, repetitive nucleotide repeat tracts (microsatellites). MSI arises either through inherited germline mutations in MMR genes (Lynch Syndrome / HNPCC, involving MLH1, MSH2, MSH6, PMS2, or EPCAM deletions) or via acquired somatic epigenetic silencing through MLH1 promoter CpG island hypermethylation in sporadic cancers. Clinical laboratory evaluation combines immunohistochemistry (IHC) for the four MMR proteins and PCR-capillary electrophoresis using the classic 5-marker Bethesda panel or mononucleotide Pentaplex panel. Biologically, dMMR/MSI-H tumors generate massive numbers of frameshift neoantigens, conferring high Tumor Mutational Burden (TMB-High) and exceptional sensitivity to immune checkpoint inhibitors (anti-PD-1 / anti-PD-L1 immunotherapy).
1. Biology of Microsatellites & DNA Replication Slippage
Microsatellites, or Short Tandem Repeats (STRs), are repetitive tracts of 1 to 6 base pair sequence motifs (e.g., $(A)_n$, $(CA)_n$, $(CAG)_n$) dispersed throughout coding and non-coding regions of the human genome.
DNA POLYMERASE REPLICATION SLIPPAGE
Normal Replication (Accurate Copying):
Template: 5'-... G A T C [ A A A A A A A A ] C T G ...-3'
Daughter: 3'-... C T A G [ T T T T T T T T ] G A C ...-5' (Matched)
Slippage: Transient Dissociation & Loop Formation:
Template: 5'-... G A T C [ A A A A A A A A ] C T G ...-3'
/---\ <-- 1-nt Insertion Loop (IDL)
Daughter: 3'-... C T A G [ T T T T T T T T T ] G A C ...-5' (Loop in nascent strand -> +1 Insertion)
\---/
*** Intact MMR System: MutSα/MutLα recognizes loop -> Excises error -> Restores wild-type ***
*** Deficient MMR (dMMR): Error uncorrected -> Permanent frameshift insertion or deletion! ***
- Replication Slippage Mechanism: During S-phase replication of homopolymer or dinucleotide repeats, DNA polymerases $\delta$ and $\epsilon$ frequently undergo transient pausing, dissociation, and misaligned reannealing. If the nascent daughter strand loops out, an insertion is created; if the template strand loops out, a deletion occurs.
- Role of the MMR System: The mismatch repair pathway acts as an essential post-replicative proofreading system, reducing replication error rates by an additional $100\text{ to }1,000\text{-fold}$ (yielding an overall genomic fidelity of $<10^{-9}$ errors per base pair per division).
2. Molecular Architecture of the Human Mismatch Repair (MMR) Machinery
The MMR machinery operates via coordinated functional heterodimers that recognize DNA distortions, direct strand-specific endonuclease incisions, excise erroneous segments, and resynthesize DNA.
THE HUMAN MISMATCH REPAIR SYSTEM
[ Mismatch Recognition: MutS Heterodimers ]
/ \
MutSα (MSH2 + MSH6) MutSβ (MSH2 + MSH3)
Single base-base mispairs Larger insertion/deletion
& small 1-2 nt loops loops (2 to 8 nucleotides)
\ /
+---------------+---------------+
|
v
[ Excision Coordination: MutL Heterodimers ]
|
MutLα (MLH1 + PMS2)
(Primary Catalytic Endonuclease)
|
v
[ Excision & Resynthesis: EXO1, PCNA, RPA, Pol δ/ε, LIG1 ]
+----------------------------------------------------------------------------------------------------+
| MMR PROTEIN HETERODIMER PAIRING & DYNAMICS |
+-------------------+-------------------+-------------------+----------------------------------------+
| Heterodimer | Master / Obligate | Secondary Client | Biochemical Function & Degradation |
| Complex | Partner | Partner | Kinetics |
+-------------------+-------------------+-------------------+----------------------------------------+
| **MutSα** | **MSH2** | **MSH6** | Binds single base mispairs & 1-2 nt IDLs.|
| | (Stable monomer) | (Unstable monomer)| Loss of MSH2 -> MSH6 degraded (Loss of both)|
| | | | Loss of MSH6 -> MSH2 stays with MSH3 |
+-------------------+-------------------+-------------------+----------------------------------------+
| **MutSβ** | **MSH2** | **MSH3** | Binds 2–8 nucleotide loop structures. |
| | (Stable monomer) | (Unstable monomer)| Secondary recognition complex |
+-------------------+-------------------+-------------------+----------------------------------------+
| **MutLα** | **MLH1** | **PMS2** | Primary catalytic endonuclease complex.|
| | (Stable monomer) | (Unstable monomer)| Loss of MLH1 -> PMS2 degraded (Loss of both)|
| | | | Loss of PMS2 -> MLH1 stays with PMS1 |
+-------------------+-------------------+-------------------+----------------------------------------+
The Obligate vs. Secondary Partner Principle
- MSH2 and MLH1 are the master, obligate structural anchors of the MutS and MutL complexes.
- MSH6 and PMS2 are unstable client proteins that cannot exist stably as uncomplexed monomers; in the absence of their obligate partners, they are rapidly targeted for proteasomal degradation.
- Immunohistochemical (IHC) Staining Patterns:
- Inactivating mutation or hypermethylation of MLH1 $\rightarrow$ Concurrent loss of both MLH1 and PMS2 staining.
- Inactivating mutation of MSH2 $\rightarrow$ Concurrent loss of both MSH2 and MSH6 staining.
- Isolated mutation in PMS2 $\rightarrow$ Isolated loss of PMS2 only (MLH1 remains intact).
- Isolated mutation in MSH6 $\rightarrow$ Isolated loss of MSH6 only (MSH2 remains intact).
3. Etiology: Hereditary Lynch Syndrome vs. Sporadic MSI
Microsatellite Instability occurs in approximately $15%$ of all colorectal cancers (CRCs) and $20–30%$ of endometrial carcinomas, divided into two distinct etiologic groups:
ETIOLOGY OF MSI IN COLORECTAL CANCER
Total MSI-H / dMMR Tumors (100%)
/ \
/ \
[ Sporadic MSI-H (~80–85%) ] [ Lynch Syndrome (~15–20%) ]
- Somatic MLH1 Promoter Hypermethylation - Germline mutation: MLH1, MSH2, MSH6, PMS2
- CpG Island Methylator Phenotype (CIMP) - EPCAM 3'-deletion (MSH2 silencing)
- BRAF V600E Mutation Present (~60–70%) - BRAF V600E Mutation Absent!
- Older age (>70 yrs), Female, Right colon - Younger age (<50 yrs), Family history
Lynch Syndrome (HNPCC)
- Inheritance: Autosomal dominant inheritance of a germline loss-of-function mutation in one allele of MLH1, MSH2, MSH6, or PMS2.
- The EPCAM Deletion Mechanism: Germline deletions involving the 3' polyadenylation signal of the upstream EPCAM (Epithelial Cell Adhesion Molecule) gene result in transcriptional read-through into the neighboring MSH2 promoter. This transcriptional collision drives somatic de novo epigenetic hypermethylation and permanent silencing of MSH2, phenocopying an MSH2 loss-of-function mutation.
- Tumor Spectrum: Colorectal cancer (lifetime risk up to 70–80%), endometrial cancer (lifetime risk 40–60%), ovarian, gastric, small bowel, hepatobiliary, and urothelial (renal pelvis/ureter) carcinomas.
The Universal Reflex Testing Algorithm
Because clinicopathologic criteria (Amsterdam II, Bethesda guidelines) miss up to $30%$ of Lynch syndrome patients, professional guidelines mandate universal screening for all newly diagnosed colorectal and endometrial carcinomas.
UNIVERSAL REFLEX SCREENING ALGORITHM
[ All Newly Diagnosed CRC / Endometrial ]
|
v
[ Initial IHC (4-Antibody Panel) ]
|
+---------------------------------+---------------------------------+
| |
All 4 Intact (pMMR) Loss of MLH1 & PMS2
(MSS / Normal) |
v
[ BRAF V600E & MLH1 Methylation ]
|
+-------------------------------+-------------------------------+
| |
BRAF V600E POSITIVE or BRAF V600E NEGATIVE &
MLH1 PROMOTER HYPERMETHYLATED MLH1 PROMOTER UNMETHYLATED
| |
v v
[ SPORADIC MSI-H ] [ SUSPECT LYNCH SYNDROME ]
(Lynch Syndrome Ruled Out!) (Refer for Germline Testing!)
The BRAF Rule in Colorectal Cancer: Somatic BRAF V600E mutations virtually never occur in Lynch syndrome colorectal tumors. Therefore, identifying a BRAF V600E mutation in an MLH1-deficient CRC confirms a sporadic etiology and effectively rules out Lynch syndrome in $>99%$ of cases.
4. Laboratory Diagnostic Assays for MSI & MMR
+----------------------------------------------------------------------------------------------------+
| MSI & MMR DIAGNOSTIC ASSAY COMPARISON |
+-------------------+-------------------+-------------------+----------------------------------------+
| Assay Modality | Markers / Targets | Assay Principle | Interpretation & Diagnostic Thresholds |
+-------------------+-------------------+-------------------+----------------------------------------+
| **Immunohistochem-| 4 Antibodies: | Evaluates nuclear | **pMMR**: Intact nuclear staining |
| istry (IHC)** | MLH1, MSH2, | protein expression| in tumor cells; **dMMR**: Complete loss|
| | MSH6, PMS2 | via antibody DAB | of nuclear staining in tumor nuclei |
| | | chromogen | with intact internal positive control |
+-------------------+-------------------+-------------------+----------------------------------------+
| **Bethesda PCR | 2 Mononucleotide | Multiplex PCR and | **MSI-H**: >= 40% (>= 2 of 5) unstable |
| Panel (NCI-5)** | (BAT-25, BAT-26) | capillary electro-| **MSI-L**: < 40% (1 of 5) unstable |
| | 3 Dinucleotide | phoresis of tumor | **MSS**: 0 of 5 markers unstable |
| | (D2S123, D5S346, | vs matched normal | (Requires matched normal tissue) |
| | D17S250) | genomic DNA | |
+-------------------+-------------------+-------------------+----------------------------------------+
| **Promega | 5 Mononucleotide: | Multiplex PCR of | **MSI-H**: >= 2 of 5 markers unstable |
| Pentaplex Panel** | BAT-25, BAT-26, | quasimonomorphic | **MSS**: 0 of 5 markers unstable |
| | NR-21, NR-24, | mononucleotides; | Higher sensitivity and specificity; |
| | MONO-27 | CE fragment sizing| often interpreted without normal tissue|
+-------------------+-------------------+-------------------+----------------------------------------+
| **Next-Generation | Hundreds of | Computational | **MSI-High Score**: High fraction of |
| Sequencing (NGS)**| microsatellite | algorithms | unstable loci; highly concordant with |
| | loci across panel | (mSINGS, MSIsensor)| PCR; evaluates TMB simultaneously |
+-------------------+-------------------+-------------------+----------------------------------------+
CAPILLARY ELECTROPHEROGRAM PROFILES
[ Normal Germline Allele ] [ MSI-H Tumor Allele ]
Single discrete peak with Novel shorter/longer deletion peaks
expected stutter pattern and peak broadening (Novel alleles!)
Fluorescence Fluorescence
^ ^
| | | |
| ||| | ||| || <-- Novel Instability Peak
| ||||| | ||||| ||||
+---------------------> Size (bp) +---------------------> Size (bp)
5. Clinical & Therapeutic Implications: Immunotherapy & Chemotherapy
- Immune Checkpoint Inhibitor Hypersensitivity:
- Deficient MMR causes uncorrected insertion/deletion mutations within coding microsatellites of crucial genes (e.g., TGFBR2, BAX, CASP5), generating frameshift peptides.
- These aberrant peptides serve as potent foreign neoantigens, stimulating dense infiltration by cytotoxic CD8+ Tumor-Infiltrating Lymphocytes (TILs).
- In response to chronic immune attack, tumor cells upregulate PD-L1 to suppress T-cells. Blocking the PD-1 / PD-L1 pathway with monoclonal antibodies (Pembrolizumab, Dostarlimab, Nivolumab) unleashes T-cell cytolytic activity, producing objective response rates $>40–60%$ and durable remissions.
- In 2017, the FDA granted accelerated tissue-agnostic approval to Pembrolizumab for any advanced, unresectable or metastatic MSI-H / dMMR solid tumor regardless of anatomic origin.
- Resistance to 5-Fluorouracil (5-FU) in Early-Stage Colorectal Cancer:
- Patients with stage II dMMR colorectal cancer exhibit an overall favorable prognosis compared to proficient MMR (pMMR) patients.
- However, stage II dMMR tumors do not derive survival benefit from adjuvant 5-FU monotherapy and may exhibit adverse outcomes; single-agent fluoropyrimidine chemotherapy is therefore omitted in stage II dMMR CRC.
Immunohistochemical (IHC) screening of a newly resected right-sided colon adenocarcinoma from a 72-year-old female reveals complete loss of nuclear staining for both MLH1 and PMS2 proteins, while MSH2 and MSH6 remain intact. Internal positive controls (stroma and lymphocytes) stain appropriately. What is the mandatory next molecular testing step, and how does it distinguish sporadic cancer from Lynch syndrome?
A clinical laboratory evaluates a tumor specimen for microsatellite instability using the classic 5-marker Bethesda panel (BAT-25, BAT-26, D2S123, D5S346, D17S250) via PCR and capillary electrophoresis. Analysis shows novel instability peaks and allele size shifts in BAT-25, BAT-26, and D5S346 compared to matched normal germline DNA. How should this tumor be classified, and what is its expected response to immune checkpoint inhibitor therapy?
Why does an inactivating mutation in the MSH2 gene result in the concurrent immunohistochemical loss of both MSH2 and MSH6 proteins, whereas an inactivating mutation in MSH6 results only in the isolated loss of MSH6?